Inogen updates investors on Voxi 5, Simeox progress 

GOLETA, Calif. - Inogen is building a foundation for its Voxi 5 stationary oxygen concentrator in the second half of 2025 that will pave the way for it to be a “2026 event,” says Michael Bourque, executive vice president, CFO and corporate treasurer.   

In the third quarter, Inogen accelerated the roll out the Voxi 5, which was developed in collaboration with Yuwell. Early feedback on the device has been positive, especially from durable medical equipment (DME) providers who commonly offer both stationary and portable oxygen concentrators. 

“We see this as something that’s going to continue to build and scale,” said Bourque during a conference call to discuss third quarter 2025 financial results. “We’ve started some of the scaling process in the back end of this year. We’ve had some initial sales coming from it, although it’s not a material impact yet. We see that coming in ‘26 and contributing growth beyond ‘26, as well.” 

Inogen announced the collaboration with Yuwell earlier this year, saying it would broaden its product portfolio through the distribution of certain respiratory products in the United States, expand and enhance its innovation pipeline through joint R&D efforts and accelerate its entry into the Chinese market.   

Inogen is also making strides with the launch of its Simeox 200 airway clearance device, which received 510(k) clearance from the U.S. Food and Drug Administration last year. The company has initiated a limited marketing release (LMR) in the United States, a key step toward securing Medicare reimbursement. 

“We’ve started the first phase of our LMR and that is working through the prescriber channel – calling on physicians and building those first experiences with the Simeox here in the United States – which is important for us to inform the clinical trial and make sure we’re able to maximize the reimbursement level,” Bourque said. 

Outside the U.S., Inogen is enrolling patients in clinical trials in Europe and China, with the goal of advancing reimbursement and commercialization pathways in those regions. 

“At the right time, we’ll give you more clarity on timelines,” Bourque said.